Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Emergent Biosolutions (NY: EBS )

1.940 +0.080 (+4.30%)
Streaming Delayed Price Updated: 11:24 AM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent Biosolutions

< Previous 1 2 3 4 Next >
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors 
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Inc. (NYSE: EBS) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces CEO Transition
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Financial Results For First Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
From Emergent BioSolutions
Via GlobeNewswire
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.